Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Phone919-855-2100
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees9
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
Tenax Therapeutics (NASDAQ:TENX) Frequently Asked Questions
What is Tenax Therapeutics' stock symbol?
Tenax Therapeutics trades on the NASDAQ under the ticker symbol "TENX."
When did Tenax Therapeutics' stock split? How did Tenax Therapeutics' stock split work?
Tenax Therapeutics's stock reverse split on the morning of Monday, February 26th 2018. The 1-20 reverse split was announced on Friday, February 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 23rd 2018. An investor that had 100 shares of Tenax Therapeutics stock prior to the reverse split would have 5 shares after the split.
How were Tenax Therapeutics' earnings last quarter?
Tenax Therapeutics Inc (NASDAQ:TENX) released its quarterly earnings data on Wednesday, August, 14th. The specialty pharmaceutical company reported ($0.28) EPS for the quarter, topping the Zacks' consensus estimate of ($0.45) by $0.17. View Tenax Therapeutics' Earnings History.
When is Tenax Therapeutics' next earnings date?
Has Tenax Therapeutics been receiving favorable news coverage?
News stories about TENX stock have trended somewhat negative recently, InfoTrie reports. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Tenax Therapeutics earned a daily sentiment score of -1.5 on InfoTrie's scale. They also gave news headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Tenax Therapeutics.
Are investors shorting Tenax Therapeutics?
Tenax Therapeutics saw a decrease in short interest in the month of September. As of September 15th, there was short interest totalling 136,500 shares, a decrease of 24.8% from the August 15th total of 181,500 shares. Based on an average trading volume of 82,800 shares, the short-interest ratio is currently 1.6 days. Approximately 2.0% of the company's shares are sold short. View Tenax Therapeutics' Current Options Chain.
Who are some of Tenax Therapeutics' key competitors?
What other stocks do shareholders of Tenax Therapeutics own?
Who are Tenax Therapeutics' key executives?
Tenax Therapeutics' management team includes the folowing people:
- Mr. Anthony A. DiTonno, CEO & Director (Age 71)
- Mr. Michael B. Jebsen, Pres & CFO (Age 48)
- Ms. Nancy J. M. Hecox, Exec. VP of Legal Affairs, Gen. Counsel & Corp. Sec.
- Maria Isabel Tomargo, Assistant VP of Marketing & Sales
- Mr. Robert F. Diegelmann, Head of New Wound Care Division
How do I buy shares of Tenax Therapeutics?
Shares of TENX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Tenax Therapeutics' stock price today?
One share of TENX stock can currently be purchased for approximately $1.24.
How big of a company is Tenax Therapeutics?
Tenax Therapeutics has a market capitalization of $8.36 million. The specialty pharmaceutical company earns $-6,810,000.00 in net income (profit) each year or ($9.04) on an earnings per share basis. Tenax Therapeutics employs 9 workers across the globe.View Additional Information About Tenax Therapeutics.
What is Tenax Therapeutics' official website?
How can I contact Tenax Therapeutics?
Tenax Therapeutics' mailing address is ONE COPLEY PARKWAY SUITE 490, MORRISVILLE NC, 27560. The specialty pharmaceutical company can be reached via phone at 919-855-2100 or via email at [email protected]
MarketBeat Community Rating for Tenax Therapeutics (NASDAQ TENX)
MarketBeat's community ratings are surveys of what our community members think about Tenax Therapeutics and other stocks. Vote "Outperform" if you believe TENX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TENX will underperform the S&P 500 over the long term. You may vote once every thirty days.
